Literature DB >> 21074946

Angiogenic suppression of osteoclasts may play a role in developing bisphosphonate-related osteonecrosis of the jaw.

Guozhu Yin1, Yun Bai, En Luo.   

Abstract

Since it was firstly reported in 2003, a large number of cases have been published concerning bisphosphonate-related osteonecrosis of the jaw (BRONJ). It has generated great interest in the medical and research communities yet remains an enigma, given its unknown pathogenesis. Many hypotheses concerning the underlying pathophysiology are discussed, including two most popular hypotheses: bone remodeling suppression and angiogenesis suppression, but none of them could explain all the unique characters of BRONJ. Bisphosphonates are potent osteoclast inhibitors, and recent studies revealed that osteoclasts were important for bone angiogenesis. Therefore, we hypothesize that bisphosphonates could inhibit osteoclast stimulation of angiogenesis, which plays an important role in developing BRONJ. Our hypothesis could help to explain some unintelligible characters of BRONJ, and deserves further studies.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21074946     DOI: 10.1016/j.mehy.2010.10.036

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  10 in total

1.  Osteonecrosis and atypical fractures-common origins?

Authors:  G Subramanian; J C Fritton; S Y P Quek
Journal:  Osteoporos Int       Date:  2012-03-10       Impact factor: 4.507

2.  Bisphosphonates and osteonecrosis: an open matter.

Authors:  Paolo Vescovi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-12-20

3.  Orofacial manifestations of SAPHO syndrome: a systematic review of case reports.

Authors:  Clémence Ferreira-Vilaca; Leonor Costa Mendes; Sophie-Caroline Campana; Isabelle Bailleul-Forestier; Christine Audouin-Pajot; Rémi Esclassan; Thibault Canceill
Journal:  Clin Rheumatol       Date:  2020-05-09       Impact factor: 2.980

4.  Osteonecrosis of the jaws in 194 patients who have undergone intravenous bisphosphonate therapy in Spain.

Authors:  Carmen Vidal-Real; Mario Pérez-Sayáns; José-Manuel Suárez-Peñaranda; José-Manuel Gándara-Rey; Abel García-García
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2015-05-01

5.  Regulation of VEGF by mevalonate pathway inhibition in breast cancer.

Authors:  Tilman D Rachner; Andy Göbel; Maria Junker; Josefa Hötzel; Peggy Benad-Mehner; Peyman Hadji; Lorenz C Hofbauer
Journal:  J Bone Oncol       Date:  2013-06-07       Impact factor: 4.072

6.  Local delivery of hydrogel encapsulated vascular endothelial growth factor for the prevention of medication-related osteonecrosis of the jaw.

Authors:  Dileep Sharma; Stephen Hamlet; Cedryck Vaquette; Eugen Bogdan Petcu; Poornima Ramamurthy; Saso Ivanovski
Journal:  Sci Rep       Date:  2021-12-03       Impact factor: 4.379

7.  Assessment of Knowledge, Awareness, and Perception of Platelet-Rich Plasma among Oral Surgeons.

Authors:  Sujithraj Stephen; Selvakumar Ramar; Chinnaiah Rajendran; Nirmala Mrugesh Devar; I Bevin Shaga; Revathi Somasundaram; Bhuvaneswari Mani; Nagappan Nagappan; S M M Moulvi
Journal:  J Pharm Bioallied Sci       Date:  2022-07-13

8.  Prevalence and Risk Factors of Atypical Femoral Fracture Bone Scintigraphic Feature in Patients Experiencing Bisphosphonate-Related Osteonecrosis of the Jaw.

Authors:  Chang-Hee Lee; Seung Hyun Son; Chae Moon Hong; Ju Hye Jeong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Tae-Geon Kwon; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2018-07-16

9.  Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Bruno Vincenzi; Andrea Napolitano; Alice Zoccoli; Michele Iuliani; Francesco Pantano; Nicola Papapietro; Vincenzo Denaro; Daniele Santini; Giuseppe Tonini
Journal:  J Hematol Oncol       Date:  2012-09-17       Impact factor: 17.388

10.  Platelet-rich plasma (PRP) in dental and oral surgery: from the wound healing to bone regeneration.

Authors:  Antonino Albanese; Maria E Licata; Bianca Polizzi; Giuseppina Campisi
Journal:  Immun Ageing       Date:  2013-06-13       Impact factor: 6.400

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.